NCT03942601View on ClinicalTrials.gov

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Temsirolimus

Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1

DRUG

Temsirolimus and dexamethasone sodium phosphate

Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2

Trial Locations (11)

10032

Columbia University Medical Center/NYPH, New York

19141

Einstein Medical Center, Philadelphia

27607

North Carolina Heart and Vascular, Raleigh

44106

University Hospital, Cleveland

60453

Advocate Christ Medical Center, Oak Lawn

72211

Arkansas Heart Hospital, Little Rock

77030

Baylor College of Medicine, Houston

80045

University of Colorado, Denver

80220

Rocky Mountain Veterans Administration Hospital, Denver

92868

St. Joseph Hospital of Orange Heart and Vascular Center, Orange

94121

San Francisco VA Medical Center, San Francisco

Sponsors
All Listed Sponsors
lead

Mercator MedSystems, Inc.

INDUSTRY

NCT03942601 - Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization | Biotech Hunter | Biotech Hunter